| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 05/02/2006 | US7037528 Microprecipitation method for preparing submicron suspensions |
| 05/02/2006 | US7037507 T helper cell epitopes |
| 05/02/2006 | US7037506 Vaccine accelerator factor (VAF) for improvement of vaccinations in poultry |
| 05/02/2006 | CA2334012C 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors |
| 05/02/2006 | CA2046448C Dosage form for administering a drug to effect circadian therapy |
| 04/27/2006 | WO2005034863A3 Countermeasures against malaria |
| 04/27/2006 | WO2005034853A3 Uses of interferons with altered spatial structure |
| 04/27/2006 | WO2005027847A3 Antibodies for use against sars |
| 04/27/2006 | WO2005023197A3 Methods and compositions for the prevention and treatment of genitourinary disorders, including pre-term labor and leiomyomas |
| 04/27/2006 | WO2005020909A3 Cellular depolarization and regulation of matrix metalloproteinases |
| 04/27/2006 | WO2004112705A3 Methods for treating sleep disorders |
| 04/27/2006 | WO2004087072A3 Topical l-carnitine compositions |
| 04/27/2006 | WO2003065993A8 Primary rat hepatocyte toxicity modeling |
| 04/27/2006 | US20060089335 Compositions and methods for enhancing cognitive function and synaptic plasticity |
| 04/27/2006 | US20060089310 Treatment of infections and other disorders |
| 04/27/2006 | US20060089297 Sperm specific lysozyme-like proteins |
| 04/27/2006 | US20060088893 Prostate cancer therapeutics and diagnostics based on conformers of prostatic cid phosphatase |
| 04/27/2006 | US20060088855 Methods of using FET labeled oligonucleotides that include a 3'-5' exonuclease resistant quencher domain and compositions for practicing the same |
| 04/27/2006 | US20060088561 solidifying agent consists of long chain fatty alcohol; carrier is semi-solid at rest and liquefies upon application of shear forces |
| 04/27/2006 | US20060088511 Cancer therapy sensitizer |
| 04/26/2006 | EP1649275A2 Dye solutions for use in methods to detect the prior evaporation of anhydrous ammonia and the production of illicit drugs |
| 04/26/2006 | EP1649066A2 Multiplexed molecular beacon assay for detection of pathogens |
| 04/26/2006 | EP1648914A2 Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| 04/26/2006 | EP1648913A2 Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
| 04/26/2006 | EP1648873A2 Neuroprotective macrocylic compounds and methods for their use |
| 04/26/2006 | EP1648527A2 Stabilization and ionic triggering of nitric oxide release |
| 04/26/2006 | EP1648514A2 A method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture |
| 04/26/2006 | EP1648497A2 Compositions and methods for selective dissolution of nascent intravascular blood clots |
| 04/26/2006 | EP1648495A2 Compositions comprising gastrin compounds and their use in diabetes |
| 04/26/2006 | EP1648492A2 A novel antiproliferative factor and methods of use |
| 04/26/2006 | EP1648489A2 Treatment or prevention of damage due to radiation exposure |
| 04/26/2006 | EP1648487A2 Immunotherapeutics for biodefense |
| 04/26/2006 | EP1648474A2 Methods and pharmaceutical compositions for healing wounds |
| 04/26/2006 | EP1648471A2 Methods for the treatment of male and female sexual dysfunction |
| 04/26/2006 | EP1648469A2 Antiglucocorticoids for the treatment of catatonia |
| 04/26/2006 | EP1648463A2 Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof |
| 04/26/2006 | EP1648461A2 Muscarinic acetylcholine receptor antagonists |
| 04/26/2006 | EP1648455A2 Anaplastic lymphoma kinase modulators and methods of use |
| 04/26/2006 | EP1648439A2 Antiglucocorticoid therapy for the prevention of neurological damage in premature infants |
| 04/26/2006 | EP1648427A2 Compositions and methods including a recombinant human mab that promotes cns remyelination |
| 04/26/2006 | EP1648421A2 Orally dissolving films |
| 04/26/2006 | EP1648417A2 Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
| 04/26/2006 | EP1648416A2 Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| 04/26/2006 | EP1648411A2 Pharmaceutical compositions |
| 04/26/2006 | EP1648408A1 Azepine derivatives as pharmaceutical agents |
| 04/26/2006 | EP1648406A2 Uses and formulations for transdermal or transmucosal application of active agents |
| 04/26/2006 | EP1648398A2 Combined treatments comprising synthetic peptide copolymers for preventing graft rejection |
| 04/26/2006 | EP1648397A2 Ex vivo progenitor and stem cell expansion for use in the treatment of disease of endodermally-derived organs |
| 04/26/2006 | EP1648389A2 Biological engineering of articular structures containing both cartilage and bone |
| 04/26/2006 | EP1648388A2 Novel targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax |
| 04/26/2006 | EP1648387A2 Fugetactic proteins, compositions and methods of use |
| 04/26/2006 | EP1648386A2 Transmucosal dosage forms for brain-targeted steroid chemical delivery systems |
| 04/26/2006 | EP1648385A2 System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
| 04/26/2006 | EP1648384A2 Stable aluminum/zirconium antiperspirant solution |
| 04/26/2006 | EP1648383A2 Compositions related to a novel endophytic fungi and methods of use |
| 04/26/2006 | EP1648382A2 Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
| 04/26/2006 | EP1648380A2 Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants |
| 04/26/2006 | EP1648377A2 Method of treating diabetes type ii |
| 04/26/2006 | EP1648373A2 Method and device for regulation of limbic system of the brain by means of neuro-electrical coded signals |
| 04/26/2006 | EP1648364A2 Pharmaceutical compositions for topical application |
| 04/26/2006 | EP1648232A2 Method of treating hit patients with argatroban |
| 04/26/2006 | EP1408953B1 Carbamate compounds for use in preventing or treating bipolar disorder |
| 04/26/2006 | CN1764837A Methods for predicting an individual's clinical treatment outcome from sampling a group of patients' biological profiles |
| 04/26/2006 | CN1764464A Tertiary amine functional complex polyester polymers and methods of production and use |
| 04/26/2006 | CN1764460A Method of treating cognitive decline due to sleep deprivation and stress |
| 04/26/2006 | CN1764450A Crystalline N-formyl hydroxylamine compounds |
| 04/26/2006 | CN1764445A A method of treating breast cancer with androgen receptor antagonists |
| 04/26/2006 | CN1763181A Vaccine against mumps containing a JERYL-LYNN virus strain |
| 04/26/2006 | CN1763060A Metallocene compound, indene compound and application thereof |
| 04/26/2006 | CN1762957A 2,3-dihydro-1-indene compound and preparation method thereof |
| 04/26/2006 | CN1762494A Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| 04/26/2006 | CN1762335A Rapidly disintegrating methylcellulose tablets |
| 04/26/2006 | CN1253205C 疫苗 Vaccine |
| 04/25/2006 | US7034176 Aminopropylphosphinic acids |
| 04/25/2006 | US7034126 Lactoferrin in the treatment of diabetes mellitus |
| 04/25/2006 | US7034021 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses |
| 04/25/2006 | US7034006 Use of lipid conjugates in the treatment of disease |
| 04/25/2006 | US7033603 Tissue engineering; drug delivery; fiber with hollow bore |
| 04/25/2006 | US7033593 Immunogen comprising an HIV envelope protein, a ligand and H2 peptide |
| 04/25/2006 | US7033577 Protection Factor A (PFA); determining in vivo SPF; determining in vitro SPF based on the sunscreen's absorbance spectrum in the UV region; normalizing the absorbence spectrum based on integration area of UVA1; and calculating the PFA-PPD in vitro |
| 04/25/2006 | CA2433035C Pharmaceutical compositions comprising amlodipine maleate |
| 04/20/2006 | WO2006041488A1 Immortalized hepatocytes |
| 04/20/2006 | WO2006041409A1 Medical solution, method for producing and use thereof |
| 04/20/2006 | WO2005051322A3 Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts |
| 04/20/2006 | WO2005046606A3 Compositions and methods for diagnosing and treating chronic lymphocytic leukemia |
| 04/20/2006 | WO2005030141A3 Morinda citrifolia-based oral care compositions and methods |
| 04/20/2006 | WO2004108088A3 Methods and compositions for interferon therapy |
| 04/20/2006 | WO2004091493A3 Improved heat shock protein-based vaccines and immunotherapies |
| 04/20/2006 | WO2004071420A3 Compositions and methods for less immunogenic protein formulations |
| 04/20/2006 | WO2004064732A3 The use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl |
| 04/20/2006 | US20060084682 e.g. 5-{2-[6-(3,4-Dichloro-phenyl)-pyridin-2-yl]-1H-benzoimidazol-5-ylmethylene}-2-thioxo-thiozolidin; agonists of TPO receptor; non-peptide; thrombocytopenia is due to bone marrow, stem cell, or liver transplant, idiopathic thrombocytopenia purpura, myelodysplastic syndromes, aplastic anemia or leukemia |
| 04/20/2006 | US20060084681 Substituted pyrazoles, compositions containing such compounds and methods of use |
| 04/20/2006 | US20060084651 Chemical compounds |
| 04/20/2006 | US20060083693 Stable pharmaceutical solution formulations for pressurised metered dose inhalers |
| 04/20/2006 | CA2568180A1 Medical solution, method for producing and use thereof |
| 04/20/2006 | CA2550452A1 Immortalized hepatocytes |
| 04/19/2006 | EP1647544A2 Method of obtaining inhibitors of type ii dehydroquinase enzyme and precursors thereof |
| 04/19/2006 | EP1646869A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 04/19/2006 | EP1646670A2 Self-crosslinkable poly(caprolactone fumarate) |
| 04/19/2006 | EP1646614A2 Ophthalmic compositions for treating ocular hypertension |